These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 7961537

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. New pharmacologic approaches to obsessive compulsive disorder.
    Insel TR.
    J Clin Psychiatry; 1990 Oct; 51 Suppl():47-51; discussion 56-8. PubMed ID: 2120204
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. An integrated approach to treatment of obsessive compulsive disorder.
    Greist JH.
    J Clin Psychiatry; 1992 Apr; 53 Suppl():38-41. PubMed ID: 1532963
    [Abstract] [Full Text] [Related]

  • 5. Pharmacotherapy of obsessive compulsive disorder.
    Goodman WK, McDougle CJ, Price LH.
    J Clin Psychiatry; 1992 Apr; 53 Suppl():29-37. PubMed ID: 1532962
    [Abstract] [Full Text] [Related]

  • 6. Using antipsychotic agents in older patients.
    Alexopoulos GS, Streim J, Carpenter D, Docherty JP, Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.
    J Clin Psychiatry; 2004 Apr; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [Abstract] [Full Text] [Related]

  • 7. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
    Etain B, Bonnet-Perrin E.
    Encephale; 2001 Apr; 27(3):280-9. PubMed ID: 11488259
    [Abstract] [Full Text] [Related]

  • 8. [Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study].
    Hantouche EG, Bouhassira M, Lancrenon S.
    Encephale; 2000 Apr; 26(6):73-83. PubMed ID: 11217541
    [Abstract] [Full Text] [Related]

  • 9. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L.
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Biological treatments in obsessive-compulsive disorder].
    Montgomery SA, Fineberg NA, Montgomery D.
    Encephale; 1990 Jan; 16 Spec No():335-9. PubMed ID: 2209492
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Obsessive-compulsive disorder: treatment with serotonin-selective uptake inhibitors, azapirones, and other agents.
    Murphy DL, Pato MT, Pigott TA.
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):91S-100S. PubMed ID: 1973944
    [Abstract] [Full Text] [Related]

  • 16. The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis.
    McDougle CJ, Goodman WK, Leckman JF, Price LH.
    Psychiatr Clin North Am; 1993 Dec; 16(4):749-66. PubMed ID: 8309811
    [Abstract] [Full Text] [Related]

  • 17. Treatment of obsessive compulsive disorder: psychotherapies, drugs, and other somatic treatment.
    Greist JH.
    J Clin Psychiatry; 1990 Aug; 51 Suppl():44-50; discussion 55-8. PubMed ID: 2116405
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.